The effects of BAR502, a non‐bile steroidal ligand of the Farnesoid X Receptor (FXR) and G Protein–Coupled Bile Acid Receptor 1 (GPBAR1), have been investigated on tumor proliferation and epithelial‐mesenchymal transition (EMT), with a focus on selective LIFR antagonism. The gene discussed is LIFR; the disease is neoplasm.